How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,608 results for

Anti-Retroviral Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Antiretroviral Therapy in Early HIV Infection. (Abstract)

Antiretroviral Therapy in Early HIV Infection. 26816019 2016 01 28 2018 12 02 1533-4406 374 4 2016 01 28 The New England journal of medicine N. Engl. J. Med. Antiretroviral Therapy in Early HIV Infection. 394 10.1056/NEJMc1513311 Lundgren Jens J Babiker Abdel G AG Neaton James D JD eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anti-Retroviral Agents AIM IM N Engl J Med. 2015 Aug 27;373(9):795-807 26192873 N Engl J Med. 2016 Jan 28;374(4):393 26816020 N Engl J Med. 2016 Jan (...) 28;374(4):393-4 26816021 Anti-Retroviral Agents administration & dosage Female HIV Seropositivity drug therapy Humans Male 2016 1 28 6 0 2016 1 28 6 0 2016 1 29 6 0 ppublish 26816019 10.1056/NEJMc1513311 10.1056/NEJMc1513311#SA3

2016 NEJM

182. Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy. (Abstract)

School of Public Health, Columbia University, New York. eng Editorial Comment 2015 07 20 United States N Engl J Med 0255562 0028-4793 0 Anti-Retroviral Agents 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 Aug 27;373(9):808-22 26193126 N Engl J Med. 2015 Aug 27;373(9):795-807 26192873 AIDS-Related Opportunistic Infections prevention & control Anti-Retroviral Agents administration & dosage therapeutic use Antitubercular Agents therapeutic use Female HIV Infections drug therapy (...) Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy. 26193047 2015 09 07 2018 12 02 1533-4406 373 9 2015 Aug 27 The New England journal of medicine N. Engl. J. Med. Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy. 875-6 10.1056/NEJMe1508527 Abdool Karim Salim S SS From the Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; and the Department of Epidemiology, Mailman

2015 NEJM

183. To Assess the Drug-drug Interaction Potential Between Dapivirine Vaginal Ring-004, Containing 25 mg of Dapivirine, and Clotrimazole 10 mg/g (1%)

Primary Completion Date : November 28, 2016 Actual Study Completion Date : November 28, 2016 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Treatment A Dapivirine Ring-004 for 28 days Drug: Dapivirine Ring-004 Treatment A: Dapivirine Ring-004 for 28 days Other Name: Treatment A Active Comparator: Treatment B Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 (...) : International Partnership for Microbicides, Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: IPM 036 First Posted: July 28, 2016 Last Update Posted: August 30, 2017 Last Verified: August 2017 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Additional relevant MeSH terms: Layout table for MeSH terms Dapivirine Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents

2016 Clinical Trials

184. Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Initial ARV Therapy

written informed consent. Exclusion Criteria: Female who is pregnant, breast-feeding, or of childbearing potential and disagrees to use contraception throughout the study period. Use of any of the prohibited medications or other non-informed medications (Section 5.5.2) within 30 days of study entry (Day 0). Known allergy/sensitivity to any of the study drugs. Known sensitivity to skin adhesives. Serious medical (serious infection or acute therapy for other medical illness) or psychiatric illness (...) Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Initial ARV Therapy Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Initial ARV Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2016 Clinical Trials

185. Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients

be candidates for maintenance mono-therapy due to their high potency and genetic barrier for drug resistance and possibility for once daily dosing. However, although several controlled and uncontrolled studies have been conducted to examine the safety and tolerance of PI/r monotherapy for maintenance in HIV-infected patients, many of these studies were small or did not use controls; and evidence on the efficacy and safety of PI/r monotherapy is therefore limited. Moreover, several trials have reported (...) on the market. Among potential advantages, this FDC may contribute to decrease pill burden as well as to avoid medication errors. However, according to prescribing information, darunavir/cobicistat and etravirine should not be combined due to potential drug-drug interactions. Darunavir and cobicistat are both metabolized by the isoenzyme CYP3A4 of the cytochrome P450, which is inhibited by cobicistat. On the other hand, etravirine, which is mainly metabolized by 2C19 (but also by CYP3A4 in a minor extent

2016 Clinical Trials

186. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine Full Text available with Trip Pro

assigned by NLM MeSH Adolescent; Adult; Anti-Retroviral Agents /economics /therapeutic use; Cost-Benefit Analysis; Epidemics; HIV Infections /complications /drug therapy /epidemiology; Harm Reduction; Health Care Costs; Humans; Methadone /economics /therapeutic use; Middle Aged; Models, Theoretical; Narcotics /economics /therapeutic use; Opiate Substitution Treatment /economics /methods; Prevalence; Quality-Adjusted Life Years; Risk-Taking; Substance Abuse, Intravenous /complications /drug therapy (...) it difficult to assess the authors' conclusions. Funding Supported by a grant from the National Institute on Drug Abuse, a Stanford Graduate Fellowship, and the Department of Veterans Affairs, USA. Bibliographic details Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLOS Medicine 2011; 8(3):e1000423 PubMedID DOI Original Paper URL Indexing Status Subject indexing

2011 NHS Economic Evaluation Database.

187. Alopecia Universalis Associated with Vitiligo in an 18-year-old HIV-positive Patient: Highly Active Anti-retroviral Therapy as First Choice Therapy? Full Text available with Trip Pro

Alopecia Universalis Associated with Vitiligo in an 18-year-old HIV-positive Patient: Highly Active Anti-retroviral Therapy as First Choice Therapy? 23824261 2014 09 15 2014 01 09 1651-2057 94 1 2014 Jan Acta dermato-venereologica Acta Derm. Venereol. Alopecia universalis associated with vitiligo in an 18-year-old HIV-positive patient: highly active anti-retroviral therapy as first choice therapy? 116-7 10.2340/00015555-1651 Nikolic Damjan S DS Department of Dermatology and Venereology (...) , University Hospitals, Gabrielle-Perret-Gentil 4, 1211 Geneva 14, Switzerland. Viero Daniela D Tijé Vanessa Christinet Yana VC Toutous-Trellu Laurence L eng Case Reports Journal Article Sweden Acta Derm Venereol 0370310 0001-5555 Alopecia universalis IM Adolescent Alopecia complications drug therapy Antiretroviral Therapy, Highly Active HIV Infections complications drug therapy Humans Male Vitiligo complications drug therapy 2013 7 5 6 0 2013 7 5 6 0 2014 9 16 6 0 ppublish 23824261 10.2340/00015555-1651

2013 Acta Dermato-Venereologica

188. Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

is not an exclusion criterion if it is controlled with anti-retroviral drugs that are unaffected by concomitant enzalutamide. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse; Patients who are sexually active and not willing/able to use medically acceptable forms of barrier contraception. Use of hormonal therapy or androgen deprivation therapy, including (...) as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at high risk of recurrence. Condition or disease Intervention/treatment Phase Prostatic Neoplasms Drug: Enzalutamide Drug: Conventional NSAA Drug: LHRHA Radiation: External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) Phase 3 Study Design Go to Layout table for study information

2015 Clinical Trials

189. A Open-label, Drug-Drug Interaction With Maraviroc

: Treatment Official Title: A Phase 1, Open-label, Drug-drug Interaction Study Between BMS-663068 and Maraviroc in Healthy Subjects Actual Study Start Date : July 7, 2015 Actual Primary Completion Date : September 21, 2015 Actual Study Completion Date : September 21, 2015 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Sequential Dosing Treatment A: BMS-663068 orally twice daily (BID) on Days 1 (...) : Healthy male and female nonsmoking subjects ages 18 to 50 years, inclusive with a body mass index of 18.0 to 32.0 kg/m2, inclusive Women of childbearing potential must agree to follow instructions for methods of contraception for a total of 34 days post-treatment completion Exclusion Criteria: Any condition possibly affecting drug absorption Pre-existing liver dysfunction Any significant acute or chronic medical illness Orthostatic intolerance Other protocol specified exclusion criteria could apply

2015 Clinical Trials

190. Cardiovascular Risk in HIV Patients on Antiretroviral Therapy Therapy: The MHEART Study

Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Aspirin Aspirin 325mg daily Drug: Aspirin Placebo Comparator: Placebo Placebo Drug: Placebo Outcome Measures Go to Primary Outcome Measures : Reactive Hyperemia Index [ Time Frame: Baseline, 30 days after treatment, 60 days after treatment, 90 days after treatment ] Assessment of peripheral arterial endothelial function Quantification of inflammatory biomarkers- TNF-alpha, C (...) based on physician assessment History of medication noncompliance in last 3 months Pregnancy Contraindications to aspirin Previous allergic reaction to aspirin or similar medications to aspirin Asthma with nasal congestion or nasal polyps Bleeding disorders (inherited or acquired) Chicken pox Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2015 Clinical Trials

191. A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat

Enrollment : 16 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Official Title: A Drug-drug Interaction Study Between the Novel Anti-HCV Agent Daclatasvir and the Antiretroviral Agents Atazanavir/Ritonavir or Atazanavir/Cobicistat in Healthy Volunteers Study Start Date : November 2015 Actual Primary Completion Date : January 2016 Actual Study Completion Date : January 2016 Resource links provided by the National Library of Medicine related topics (...) . Drug: Daclatasvir Other Name: Daklinza Drug: Atazanavir Other Name: Reyataz Drug: Cobicistat Other Name: Tybost Outcome Measures Go to Primary Outcome Measures : AUC [ Time Frame: up to 24 hours after administration ] Secondary Outcome Measures : Adverse events [ Time Frame: 4 weeks ] adverse events will be collected up to 4 weeks in total (entire study) Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision

2015 Clinical Trials

192. A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)

for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) Collaborator: ViiV Healthcare Information provided by (Responsible Party): French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) Study Details Study Description Go to Brief Summary: The principal objective is to evaluate the antiviral efficacy of 48 weeks treatment with the two-drugs combination dolutegravir(Tivicay (...) Virologically Suppressed With Triple HAART - ANRS 167 Lamidol Actual Study Start Date : September 17, 2015 Actual Primary Completion Date : March 2017 Actual Study Completion Date : March 2017 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: dolutegravir(Tivicay®) and lamivudine(Epivir®) Drug: dolutegravir (Tivicay®) - Phase 1 • Phase 1 (8 weeks) : switch of the third agent with dolutegravir

2015 Clinical Trials

193. Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs Full Text available with Trip Pro

Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs Anti-retroviral (ARV) -based microbicides are one of the strategies pursued to prevent HIV-1 transmission. Delivery of ARV drugs to subepithelial CD4+ T cells at concentrations for protection is likely determined by drug transporters expressed in the cervicovaginal epithelium. To define the role of drug transporters in mucosal disposition of topically applied ARV-based (...) microbicides, these must be tested in epithelial cell line-based biopharmaceutical assays factoring the effect of relevant drug transporters. We have characterised gene expression of influx and efflux drug transporters in a panel of cervicovaginal cell lines and compared this to expression in cervicovaginal tissue. We also investigated the effect of dapivirine, darunavir and tenofovir, currently at advanced stages of microbicides development, on expression of drug transporters in cell lines. Expression

2015 PloS one

194. Realising the potential of stratified medicine

. The Academy is grateful for the support of Amgen, the Association of the British Pharmaceutical Industry, GE Healthcare, the Medical Research Council, the Medicines and Healthcare products Regulatory Agency, Roche and the Technology Strategy Board. This report is published by the AMS and has been endorsed by its Officers and Council. Contributions by the oversight group were made purely in an advisory capacity. Members of the oversight group participated in an individual capacity (...) the opportunities and ongoing challenges and to propose solutions for the development and use of stratified medicine products, namely targeted drugs and their associated diagnostic tests. These were discussed and refined at a symposium in October 2012 that brought together experts from the pharmaceutical and diagnostic industries, health economists, medicines regulators, health service providers, clinical researchers, patient representatives and policy makers in the private and public sectors. A list

2013 Academy of Medical Sciences

195. Complementary, Alternative and Traditional Medicine in HIV Care

Anti-Retroviral Therapy (HAART). The Issue and Why It’s Important While HAART treatment is highly effective at reducing viral load in people living with HIV, there are a number of symptoms associated with both the treatment and disease which could be addressed through complementary and alternative medicine, including comorbidities (e.g. cardiovascular, liver and renal diseases) and mental health issues (e.g. depression). Since the beginning of the HIV epidemic, complementary and alternative (...) Contact: rapidresponse@ohtn.on.ca ? While some forms of complementary and alternative medicine do not interact with antiretroviral medications, herbal remedies have the highest potential for contraindications. The highest risk is in countries where complementary and alternative medicine is not regulated and herbal remedies are commonly used (6). While there is a low risk of interactions between complementary and alternative medicine and antiretroviral drugs, there is a potential that herbal

2013 Ontario HIV Treatment Network

196. Dental Caries Prevalence in Human Immunodeficiency Virus Infected Patients Receiving Highly Active Anti-Retroviral Therapy in Kermanshah, Iran Full Text available with Trip Pro

Dental Caries Prevalence in Human Immunodeficiency Virus Infected Patients Receiving Highly Active Anti-Retroviral Therapy in Kermanshah, Iran Introduction of new approaches for the treatment of human immunodeficiency virus (HIV) infection such as anti-retroviral medicines has resulted in an increase in the life expectancy of HIV patient. Evaluating the dental health status as a part of their general health care is needed in order to improve the quality of life in these patients. The aim (...) in all analysis.The mean and standard deviation (SD) of decayed, missed and filled teeth of those who were on highly active antiretroviral therapy was 6.86 ± 3.57, 6.39 ± 6.06 and 1.89 ± 1.93, respectively. There was no significant difference between these values regarding to the treatment of patients. The mean and standard deviation of DMFT, DMFS and the number of decayed root surfaces were 15.14 ± 6.09, 56.79 ± 28.56, and 4.96 ± 2.89 in patients treated by anti-retroviral medicine which were

2014 Cell Journal (Yakhteh)

197. Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy. Full Text available with Trip Pro

Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy. Malaria and HIV infections are both highly prevalent in sub-Saharan Africa, with HIV-infected patients being at higher risks of acquiring malaria. The majority of antiretroviral (ART) and anti-malarial drugs are metabolized by the CYP450 system, creating a chance of drug-drug interaction upon co-administration. Limited data are available on the effectiveness

2014 Malaria journal

198. Comorbidities and Virologic Outcome Among Patients on Anti-retroviral Therapy in Rural Lesotho

of Medicine related topics: Groups and Cohorts Go to Group/Cohort Patients on anti-retroviral therapy The cohort consists of patients on first-line anti-retroviral therapy since at least 6 months, followed at one of the facilities involved in the study. Outcome Measures Go to Primary Outcome Measures : Prevalence of comorbidities among patients on anti-retroviral therapy in rural Lesotho [ Time Frame: at enrollment ] The prevalence of the following comorbidities/conditions will be assessed: Diabetes (...) -line anti-retroviral therapy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02126696 Locations Layout table for location information Lesotho Seboche Hospital Butha-Buthe, Lesotho, 400 Paray Hospital Thaba-Tseka, Lesotho Sponsors and Collaborators

2014 Clinical Trials

199. A Study of MK-8591 in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)

A Study of MK-8591 in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003) A Study of MK-8591 in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. A Study of MK-8591 in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02217904 Recruitment Status : Completed First

2014 Clinical Trials

200. Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®

Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune® Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune® - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune® The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02191293 Recruitment Status : Completed First Posted : July 16, 2014 Last Update Posted : July 16, 2014 Sponsor: Boehringer Ingelheim

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>